The introduction of highly active antiretroviral drug treatment in HIV/AIDS management has been associated with reduction in opportunistic infections, morbidity, mortality and HIV transmission. Long usage of these drugs is however throwing up new challenges such as poor pattern of responses, build up of drug resistance in the virus, kidney and liver damages thus creating the need for urgent review of the management of HIV/AIDS and development of alternative treatment protocols. The present study evaluates the effect of DXL (Bioclean II) on female HIV/AIDS cases in Nigeria. The study individuals, HIV (n=5) and AIDS (n=5) were given 10.0mls of DXL twice daily orally for 8 months and monitored closely for strict adherence. Blood samples were collected at 0, 3 and 6 months intervals for analysis. The parameters evaluated were sero status, body weights, CD4+ T-cells and viral load. The viral load reduced from 299,587.6 copies/ml to 5,721.6 copies/ml to 1,114 copies/ml, the CD4+ T-cells increased from 123.2 cells/ml to 682.6 cells/ml to 752.4 cells/ml and body weights increased from 44.6kg to 56.4kg to 61.4kg. Exposure to DXL seem to have improved the CD4+T-cells count, body weights and reduced severely the viral load of the investigated individuals. There were no corresponding significant changes in their sero status. These findings suggest that DXL has a potential as an intervention tool in HIV/AIDS disease and a need for re-evaluation of available treatment models, especially if the gains made by those exposed to DXL are sustainable.
Keywords: DXL, HIV/AIDS, Treatment and Effects.